Medicine against parasites like Tapeworms and Giardia, contains a substance that kills Prostate- and colon cancer.
Cancer researchers at the University of Bergen (UiB) have in the recent years experienced with hundreds of known drugs, to see how they influence cancer cells.
Recently they found that a substance in medicine against parasites like Giardia and Tapeworms, acts like tailored medicine against prostate- and colon cancer.
“We discovered that this specific substance is blocking the signalling pathway in the cancer cells, and make them stop growing. It is not often that researchers discover a substance that targets specific molecules as precisely as this one, ” says Professor Karl-Henning Kalland at the Department of Clinical Science, at UiB. He is the leader of the Kalland´s Research Group.
The study is published in Nature Chemical Biology.
The researchers Yi Qu and Xisong Ke at Kalland team saw that the cells in prostate- and colon cancer contain high amounts of activated Beta-catenin. Activation of this protein makes the cells go amok and divides at high tempo. In addition, Beta-catenin makes the cancer cells more resistant and more able for survival.
In the study, Qu and Ke discovered that it was the substance NTZ (nitazoxanide), a well known and approved anti-parasite drug, that decompose the activated Beta-catenin.
“We are the first researchers who have mapped the complex molecular mechanisms involved in this process,” Kalland says.
Recycling old medicines
Experiments with well-known drugs show that a medicine may have different and unknown targets in the cells.
“The advantage of testing already approved drugs, is that we know they work in the human body and have no serious side effects, which means that a future treatment may happen quicker,” Kalland explains.
Strengthen the immune system
NTZ attacks cancer celles by hindering the activated Beta-catenin. It appears that this hindering also stimulates central parts of the immune system, that attacks cancer cells.
“At the moment, we are working on how to strengthen our on going immune therapy against prostate cancer by using the mechanisms we discovered of the NTZ,” Kalland says.
Kalland and his research-team is in the first phase in a clinical trial using immune therapy against prostate cancer.
Learn more: Tapeworm drug fights Prostate Cancer
The Latest on: Immune therapy
- Molecular Test That Predicts Immunotherapy Response For Kidney Cancer on February 19, 2019 at 10:04 pm
The first line of treatment for kidney cancer is immunotherapy using drugs such as PD-L1 checkpoint inhibitors. However, the procedure is expensive and helps only a subset of patients and for the majo... […]
- Birch pollen allergen immunotherapy normalizes nasal gene-expression and microbial community on February 19, 2019 at 4:04 pm
According to a new study, birch pollen allergen immunotherapy modifies the gene expression and microbiome profile of the nasal epithelium to correspond to those of healthy controls. Birch pollen aller... […]
- New machine learning technique rapidly analyzes nanomedicines for cancer immunotherapy on February 19, 2019 at 12:43 pm
SNAs are ball-like forms of DNA and RNA arranged on the surface of a nanoparticle. Credit: Chad Mirkin/Northwestern University Spherical nucleic acids are a class of personalized medicines for ... […]
- Anti-cancer immunotherapy could be used to fight HIV on February 19, 2019 at 10:29 am
Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have shown that immunotherapy treatments against cancer could reduce the amount of virus that persists in people on triple t... […]
- Global Cancer Immunotherapy Market is Projected to Reach $170.70 Billion by 2028 on February 19, 2019 at 9:00 am
FREMONT, California, Feb. 19, 2019 /PRNewswire/ -- According to a new market intelligence report by BIS Research, titled "Global Cancer Immunotherapy Market - Analysis and Forecast, 2018-2028", the ma... […]
- 'Exciting Times' With Immunotherapy for Kidney Cancer on February 19, 2019 at 8:56 am
San Francisco — Two new combination regimens are set to become new standards of care for the treatment of metastatic renal cell carcinoma (mRCC). The new combinations contain an immunotherapy and a ta... […]
- Using anti-cancer immunotherapy to fight HIV on February 19, 2019 at 8:20 am
Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have shown that immunotherapy treatments against cancer could reduce the amount of virus that persists in people on ... […]
- New Immunotherapy Clinical Trial Targets Common Mesothelioma Protein on February 19, 2019 at 7:10 am
A biotechnology company specializing in innovative cancer therapeutics has opened a clinical trial examining an immunotherapy drug targeting a protein found in 90 percent of malignant mesothelioma tum... […]
- Immunotherapy could extend survival for patients with aggressive glioblastoma brain cancer on February 19, 2019 at 4:43 am
Sen. John McCain died after a short battle against glioblastoma brain cancer. Glioblastoma — the aggressive brain cancer that killed Sen. John McCain, Sen. Ted Kennedy and Beau Biden, son of ... […]
- Cancer Immunotherapy Drug Discovery Outsourcing Market Worth $1.7 Billion by 2025: Grand View Research, Inc. on February 19, 2019 at 2:52 am
SAN FRANCISCO, Feb. 19, 2019 /PRNewswire/ -- The global cancer immunotherapy drug discovery outsourcing market size is projected to reach USD 1.7Billion by 2025, according to a new report by Grand ... […]
via Google News and Bing News